Safety and Biodistribution of Human Bone Marrow-Derived Mesenchymal Stromal Cells Injected Intrathecally in Non-Obese Diabetic Severe Combined Immunodeficiency Mice: Preclinical Study
Conclusion:This study demonstrated that intrathecal injection of hBM-MSCs is safe, non toxic and do not produce tumors. These results provide further evidence that hBM-MSCs might be used in a clinical trial in patients with FRDA.
Source: Tissue Engineering and Regenerative Medicine - Category: Biotechnology Source Type: research
More News: Ataxia | Biochemistry | Biotechnology | Brain | Clinical Trials | Diabetes | Eating Disorders & Weight Management | Endocrinology | Genetics | Heart | Hematology | Neurology | Obesity | Study | Toxicology | Transplants